Skip to content
10-K

Annual Report

10x Genomics, Inc. TXG

0001770787-25-000013

← back to feed
Filed
Feb 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Cash And Equivalents FY 2024 · Dec 31, 2024 $344.07M
Cash And Equivalents FY 2024 · Dec 31, 2023 $359.28M
Cash And Equivalents FY 2024 · Dec 31, 2022 $219.75M
Shares Outstanding FY 2024 · Dec 31, 2023 119.1M sh
Current Liabilities FY 2024 · Dec 31, 2023 $127.16M
Total Liabilities FY 2024 · Dec 31, 2023 $224.1M
Current Assets FY 2024 · Dec 31, 2023 $596.02M
Total Assets FY 2024 · Dec 31, 2023 $965.14M
Shares Diluted FY 2024 · Dec 31, 2022 113.86M sh
Capex FY 2024 · Dec 31, 2022 $131.66M
Operating Cash Flow FY 2024 · Dec 31, 2022 −$33.61M
Eps Diluted FY 2024 · Dec 31, 2022 −$1.46
Eps Basic FY 2024 · Dec 31, 2022 −$1.46
Sga Expense FY 2024 · Dec 31, 2022 $298.3M
Net Income FY 2024 · Dec 31, 2022 −$166M
Operating Income FY 2024 · Dec 31, 2022 −$167.94M
Gross Profit FY 2024 · Dec 31, 2022 $396.02M
Cost Of Revenue FY 2024 · Dec 31, 2022 $120.39M
Revenue FY 2024 · Dec 31, 2022 $516.41M
Stockholders Equity FY 2024 · Dec 31, 2021 $817.57M